Histomorphometric Analysis of the Alveolar Bone for Two Weeks after Bone Morphogenetic Protein Transfer

Mariko Kawai* and Kiyoshi Ohura
Department of Pharmacology, Osaka Dental University, Osaka, Japan

Abstract
Alveolar bone regeneration therapy is critical to retain the teeth and proper occlusion. Currently, alveolar bone loss is treated surgically using bone grafts or artificial bone, both of which carry the risk of complications, such as post-operative infection. A new, non-surgical therapy would help to improve patient safety levels and treatment success. Alveolar bone is always proceeding remodeling, and this makes it difficult for the clinicians and researchers to evaluate alveolar bone tissues after some regenerative treatments. In our previous studies, we developed a system for bone regeneration using non-viral bone morphogenetic protein (BMP) gene-expression plasmid vectors and in vivo electroporation for the ectopic bone formation in rat skeletal muscles. Here, we used bone morphometric analyses using calcein and tetracycline labelling in rats to evaluate changes in alveolar bone with our BMP gene-transfer system. We concluded that BMP-2/7 gene transfer to the periodontal tissues was an optimal therapy for the alveolar bone regeneration.

Keywords: Alveolar bone; Histomorphometric analysis; Bone labelling; Gene therapy

Introduction
Alveolar bone is pivotal for the maintenance of teeth [1]. However, when lost, alveolar bone has limited potential for spontaneous regeneration [2]. Therefore, numerous studies have investigated ways to successfully engineer new bone that is efficient and safe for clinical therapy [3]. However, because alveolar bone is in a constant state of remodeling-more so than most other bony regions-it can be difficult to evaluate whether a method has been successful in regenerating bone at the intended site [4-6]. Moreover, bone and teeth are generally more difficult to handle than other types of tissues, requiring lengthy decalcification procedures before the specimens can be assessed [7].

Previously, we developed a gene-transfer system for bone regeneration therapy by combination a non-viral BMP gene expression plasmid vector and in vivo electroporation [8,9]. Our final goal is to apply our constructed method clinically for alveolar bone regeneration [10] and to limit new bone formation to the appropriate site. Our previous study revealed that the observation for one week after BMP gene transfer to the periodontal tissues was not enough to evaluate the regenerated alveolar bone [11]. To resolve this problem, we require a suitable and reliable evaluation method to detect regenerated alveolar bone after gene therapy for continuous period of time. Here, we used a histomorphometric analysis to value alveolar bone regeneration for two weeks after BMP-2/7 gene transfer.

Aim
Aim of this study is to reveal the availability for histomorphometric analyses on the alveolar bone for two weeks after BMP gene transfer.

Materials and Methods
Gene transfer
Nine-week-old male Wistar rats (n=3) were intraperitoneally injected with calcine (10 mg/kg) on the day of gene transfer. Three days later, tetracycline hydrochloride (30 mg/kg) was intraperitoneally injected. Rats were again injected with calcine on days 6 and 12, and tetracycline on day 9, and then sacrificed with an overdose of pentobarbital sodium on day 14 (Figure 1). The maxillary regions of rats were dissected and fixed with 70% ethanol for 8 days, stained with Villanueva osteochrome bone stain for 10 days, dehydrated with increasing concentrations of ethanol, and embedded in methyl methacrylate without decalcification [13].

After polymerization, 10-µm frontal sections were obtained from the mesiobuccal crown of the upper first and second molars the region of alveolar bone surrounding the second molar was used as an untreated control for the experiment. In addition, a site of alveolar bone around the first molar away from the site of injection was also used as a control, as was the same site in the second molar. Sections were observed by fluorescence microscopy under UV irradiation for tetracycline (364 nm) and calcine (477 nm) labeling. The distances between the calcine and tetracycline labels were measured vertically at 10 points within the

*Corresponding author: Kawai M, Department of Pharmacology, Osaka Dental University, 8-1 Kuzuhahanazono-cho, Hirakata-City, Osaka, 573-1121, Japan, Tel: +81-72-864-3058; Fax: +81-72-864-3158; E-mail: kawai-m@cc.osaka-dent.ac.jp

Received November 01, 2017; Accepted November 20, 2017; Published November 30, 2017

Copyright: © 2017 Kawai M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
region in which gene transfer had been performed, using a Histometry RT Camera (System Supply, Tokyo, Japan). Statistical analyses was performed by analysis of variance (ANOVA), following by Fisher’s comparison test.

**Results**

**Villanueva bone staining**

Villanueva osteochrome bone staining was used to measure alveolar bone changes following gene transfer into the region of the first molar, comparing against the region around the second molar as an untreated control. With this staining, osteoid is transparent green to jade green or homogeneous red low-density bone is red, the nuclei of osteoblasts or osteocytes are greenish-blue to dark purple, and the cellular cytoplasm green or light green represented the cytoplasm. After BMP-2/7 gene transfer, we found no significant differences in osteoid or low-density bone formation between the alveolar bones of the first molars and second molars (Figure 2A and 2B). However, in comparing the morphology of the osteoblasts, numerous osteoblasts in the alveolar bone around the first molars were cuboidal in shape (Figure 2A arrow), typical of active osteoblasts. In contrast, osteoblasts in the alveolar bone of the second molar were squamous-like, reminiscent of lining cells (Figure 2B, arrow).

**Bone labeling and MAR**

We found five labels in the alveolar bones of the first molars and second molars (Figures 3A and 3B). We measured the distances between each label (Mineral Apposition Rate: MAR) and compared them between the alveolar bones of the first molars and second molars. The MAR values for the first molar with BMP-2/7 from 0–3 days, 3–6 days, 6–9 days and 9–12 days after gene transfer were significantly different to those for the second molar (Figure 4A). In comparison, the MAR for the uninjected control sites of both the first and second molars was not significantly different (Figure 4B).

**Figure 1:** Schematic of the double bone staining protocol used in our study. Calcein and tetracycline were intraperitoneally injected alternatively every 3 days and the distances between the stains were measured and used to determine the mineral apposition rate.

**Figure 2:** Villanueva bone staining. Alveolar bone surrounding the (A) first and (B) second (control) molars. Rats received the BMP-2/7 gene transfer injection at “a”. Position “c” marks the same site in the second molar; “b” marks a control side of the first molar where the injection was not given; and “d” marks the same site in the second molar. Scale, 100 µm.

**Figure 3:** Double bone staining. (A) Representative images of calcein and tetracycline double bone staining of the alveolar bone in the first molar. “a” marks the site of injection for BMP-2/7 gene transfer and “b” shows the control site (area not injected) of the alveolar bone in the first molar. (B) Representative images of double bone staining of alveolar bone of the second molar. “c” marks the same position as the site of injection in “a”; “d” is the control site, as in “b”. Transparent green to jade green or homogeneous red is osteoid, red is low-density bone, greenish-blue to dark purple marks the nuclei of osteoblasts or osteocytes, and green or light green marks the cytoplasm. Scale, 200 µm.

**Figure 4:** Mineral apposition rate (MAR). (A) MAR in the alveolar bone of the first molars following BMP-2/7 gene transfer (black columns), and alveolar bone at the same position in the second molars (gray columns). (B) MAR of the control sites in the alveolar bones of the first and second molars.
Discussion

We transferred a BMP-2/7 non-viral vector into the periodontal tissues of the first molars of rats with electroporation, and found that BMP-2/7 gene transfer can increase the MAR of alveolar bone. Moreover, the influence of BMP-2/7 gene transfer was limited to the targeted region of alveolar bone, without affecting adjacent alveolar bone of the second molar. In the past, gene therapy has been used to target a general change rather than a local change [14-16]. However, in alveolar tissues, it is very important that BMP-2/7 gene transfer targets only the intended periodontal tissues and not the surrounding regions, which lie adjacent to the site of interest.

Preparing bone samples for histological analysis can require an extensive processing time because of the need to decalcify the samples [17]. Moreover, histological staining of sections with hematoxylin and eosin demonstrates only a snapshot or the fragmental changes in bone tissue growth. Histomorphometric analyses with the use of dyes can reveal the time-dependent changes in bone formation [18]. This is an important distinction, as alveolar bone is always remodeling and changing [19]. Therefore, histomorphometric analyses offer a suitable way to evaluate potential alveolar bone regeneration [20].

In our previous study, although we found the inflammatory cells until three days in the target site, new bone like tissues were formed on day five after BMP-2/7 gene transfer [11]. Our final goal is to apply our alveolar bone regeneration system for the patients are under the control of the periodontitis.

Conclusion

Our histomorphometric analyses revealed that BMP-2/7 gene transfer by in vivo electroporation could increase the potential for alveolar bone regeneration at specific periodontal tissues sites. This method may represent a new clinical therapy for alveolar bone regeneration.

Acknowledgements

This study was supported by Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (Basic Research B Number 24300182) and the Daiwa Health Sciences Foundation.

References

1. Intini G, Katsuragi Y, Kirkwiid KL, Yang S (2014) Alveolar bone loss: mechanisms, potential therapeutic targets, and interventions. Adv Dent Res 26: 38-46.
2. Du J, Li M (2017) Functions of periostin in dental tissues and its role in periodontal tissue’s regeneration. Cell Mol Life Sci 74: 4279-4286.
3. Mardas N, Dereka X, Donos N, Dard M (2014) Experimental model for bone regeneration in cranio-maxillo-facial surgery. J Invest Surg 27: 32-49.
4. Peric M, Durnic-Cule L, Grcevic D (2015) The rational use of animal models in the evaluation of novel bone regenerative therapies. Bone 70: 73-86.
5. Li Z, Muller R, Rufioni D (2017) Bone remodeling and mechanobiology around implants: Insights from small animal imaging. J Orthop Res 35: 6.
6. Husain A, Jeffries MA (2017) Epigenetics and bone remodelling. Curr Osteoporos Rep 15: 450-458.
7. Mashiba T (2011) Morphological analysis of bone dynamics and metabolic bone disease. Histological findings in animal fracture model-effects of osteoporosis treatment drugs on fracture healing process. Clin Calcium 21: 551-558.
8. Kawai M, Beesho K, Kihara S, Sonobe J, Oda K, et al. (2003) Ectopic bone formation by human bone morphogenetic protein-2 gene transfer to skeletal muscle using transcutaneous electroporation. Hum Gene Ther 14: 1547-1556.
9. Kawai M, Maruyama H, Beesho K, Yamamoto H, Miyazaki J, et al. (2009) Simple strategy for bone regeneration with a BMP-2/7 gene expression cassette vector. Biochem Biophys Res Commun 390: 1012-1017.
10. Kawai M, Ohura K (2016) Gene therapy using non-viral gene expression vector and in vivo electroporation for bone regeneration: Challenge to gene transfer into the periodontal tissues. J Biomed Enger Biosci 3: 18-21.
11. Kawai M, Kataoka Y, Sonobe J, Yamamoto H, Inubashi M, et al. (2017) Non-surgical model for alveolar bone regeneration by bone morphogenetic protein-2/7 gene therapy. J Periodontol 18: 1-18.
12. Yamamoto H, Kawai M, Shiotsu N, Watanabe M, Yoshida Y, et al. (2012) BMP-2 gene transfer under various conditions with in vivo electroporation and bone induction. Asian J Oral Maxillo Surg. 24: 49-53.
13. Kawai M, Ohura K (2017) Applicability of histomorphometry analysis for evaluating alveolar bone regeneration after gene transfer. J Histol Histopathol Res 1: 21-22.
14. Dobayashi M, Goda K, Maruyama H, Fujisawa M (2005) Erythropoietin gene transfer into rat testes by in vivo electroporation may reduce the risk of germ cell loss caused by cryptorchidism. Asian J Androl. 7: 369-373.
15. Abe S, Hanawa H, Hayashi M, Yoshida T, Komura S, et al. (2005) Prevention of experimental autoimmune myocarditis by hydrodynamics-based naked plasmid DNA encoding CTLA4-lg gene delivery. J Card Fail 11: 557-564.
16. Ataka K, Maruyama H, Neichi T, Miyazaki J, Geijyo F (2003) Effects of erythropoietin -gene electrotransfer in rats with adenine-induced renal failure. Am J Nephrol 23: 315-323.
17. Endo N, Yamamoto T, Seki A, Ozawa E, Sano H (2014) Modern bone histomorphometry. Nigata: We Net Company 5: 8-77.
18. Yamamoto, Shimakura T, Takahashi H (2015) Bone cell biology assessment by microscopic approach. Bone histomorphometry of remodelling, modelling and minimodeling. Clin Calcium 25: 1491-1497.
19. Xiao W, Wang Y, Pacios S, Li S, Graves DT (2016) Cellular and molecular aspects of bone remodelling. Front Oral Biol 18: 9-16.